Search results
Lixte Biotechnology inks deal for cancer drug trial By Investing.com
Investing.com· 4 days agoLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) has entered into a significant agreement with the...
Should You Buy the Dip on Compass Pathways Stock?
Motley Fool via Yahoo Finance· 6 days agoThe biotech also has enough money on its balance sheet to adjust its course to avoid the same problems. Its cash, equivalents, and short-term investments...
Kymera shares hold Buy rating on PoC data By Investing.com
Investing.com· 1 day agoOn Monday, H.C. Wainwright maintained its Buy rating on Kymera Therapeutics (NASDAQ:KYMR) with a...
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 4 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
Oppenheimer cuts Spruce Biosciences shares target, cites updated revenue forecasts By Investing.com
Investing.com· 5 days agoOn Thursday, Oppenheimer adjusted its price target for Spruce Biosciences, Inc. (NASDAQ:SPRB)...
GameStop Analyst Lowers Price Target After 'Rambling Presentation By Roaring Kitty': Does Video Game...
Benzinga via Yahoo Finance· 6 days agoShares of video game retailer GameStop Corporation (NYSE:GME) have traded higher in recent weeks on...
Citi maintains Buy rating on Cabaletta Bio post-EULAR data By Investing.com
Investing.com· 1 day agoOn Monday, Citi reaffirmed its positive stance on Cabaletta Bio Inc . The endorsement follows the...
2025 Toyota Crown Signia Wagonish New Model
The Auto Channel· 4 days agoThe first-ever 2025 Toyota Crown Signia brings striking style and fashionable function to Toyota’s SUV lineup. With a flowing silhouette, spacious...
Eating more choline may help lower heart disease risk
MedicalNewsToday via AOL· 6 days agoNews research suggests that consuming a moderate amount of choline through foods such as eggs,...
Catastrophe Bonds as Portfolio Diversifiers: Pros and Cons
Morningstar· 6 days agoThe holy grail of investments is one with a risk premium that is uncorrelated with the economic cycle risks associated with traditional stocks and bonds. Cat bonds are income instruments typically ...
